Zacks upgrades USANA Health Sciences stock from strong sell to hold

Published on 10/20/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter sales were USD 223.27 million versus USD 235.00 million consensus. USANA Health Sciences stock costs EUR 13.30 on October 20, 2026.

Credit terms and earnings calendar

Zacks Research moved its USANA rating from strong sell to hold on October 7, 2026.
Second-quarter revenue was USD 223.27 million against USD 235.00 million consensus.
USANA Health Sciences stock traded at EUR 13.30 at 2:31 p.m. CEST at Lang & Schwarz on October 20, 2026.

USNA, US90328M1071, Illustration mit AI erstellt.

USANA Health Sciences (ISIN US90328M1071) was quoted at EUR 13.30 at Lang & Schwarz on October 20, 2026 at 2:31 p.m. CEST. MarketBeat reported that Zacks Research upgraded USANA from strong sell to hold on October 7, 2026. The change puts the rating decision alongside a weak second-quarter earnings comparison.

Quarterly figures set the backdrop

USANA reported USD 223.27 million in second-quarter 2026 net sales for the period ended July 4, 2026, while diluted earnings per share were minus USD 1.16. Those figures appear on the company's USANA investor-relations page.

The revenue figure was below the USD 235.00 million consensus cited by MarketBeat. The USD 11.73 million gap gives the rating upgrade a more cautious operating backdrop than the change from strong sell to hold suggests.

Three dated developments

On August 4, 2026, USANA reported second-quarter sales of USD 223.27 million and diluted earnings per share of minus USD 1.16, according to USANA. On October 5, 2026, the company disclosed a USD 75.00 million revolving credit facility that can be expanded to USD 200.00 million and matures on June 27, 2030, according to the SEC. On October 7, 2026, Zacks Research upgraded the stock from strong sell to hold, as reported by MarketBeat.

What does the credit change require?

Beginning with the fiscal quarter ending October 3, 2026, USANA must maintain at least USD 100.00 million in trailing four-quarter consolidated EBITDA. The threshold falls to USD 70.00 million when revolving exposure is USD 50.00 million or less, while the annual general asset sale limit rises from USD 500,000 to USD 2.50 million, according to the SEC.

Upcoming dates are already set

USANA is scheduled to release third-quarter 2026 results after the market close on November 3, 2026. The conference call is scheduled for November 4, 2026 at 11:00 a.m. ET, according to the company's investor-relations page.

USNA price context for investors

On the NYSE, USNA was last at USD 14.89 on October 19, 2026 at 4:00 p.m. ET in after-hours trading. The US stock had a market capitalization of USD 275.1 million on that date.

USANA Health Sciences stock was trading at EUR 13.30 at Lang & Schwarz on October 20, 2026 at 2:31 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of USANA Health Sciences stock.